Regeneron Pharmaceuticals Inc (REGN) stock forecast · P/E 14, rev $4.29B
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US. It is led by Leonard S. Schleifer M.D., Ph.D..
This REGN forecast page states what the cached financials imply — not a price target and not a guarantee. Regeneron Pharmaceuticals Inc outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
The near-term path: Revenue was up 19.0% from 2026-03-31 to 2026-06-30. A forecast that ignores that change is just a story.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next REGN 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the REGN stock page.
Not investment advice.